title: Effects of traditional Chinese patent medicine on essential hypertension: a systematic review.
abstract: Traditional Chinese patent medicine (TCPM) is widely used for essential hypertension (EH) in China. However, there is no critically appraised evidence, such as systematic reviews or meta-analyses, regarding the potential benefits and disadvantages of TCPM to justify their clinical use and recommendation. The aim of this review was to systematically evaluate and meta-analyze the effects of TCPM for EH. Seven databases, the Cochrane Library, PubMed, EMBASE, the China National Knowledge Infrastructure, the Chinese Scientific Journal Database, the Chinese Biomedical Literature Database, and the Wanfang Database, were searched from their inception to August 2014 for relevant studies that compared one TCPM plus antihypertensive drugs versus antihypertensive drugs alone. The methodological quality of the included trials was assessed using the Cochrane risk-of-bias tool. The primary outcome measures were mortality or progression to severe complications and adverse events. The secondary outcome measures were blood pressure (BP) and quality of life (QOL). Seventy-three trials, which included 8138 patients, on 17 TCPMs were included. In general, the methodological quality was low. Two trials evaluated the effects of TCPMs on mortality and the progression to severe complications after treatment, and no significant difference was identified compared with antihypertensive drugs alone. No severe adverse events were reported. Thirteen TCPMs used in complementary therapy significantly decreased systolic BP by 3.94 to 13.50 mmHg and diastolic BP by 2.28 to 11.25 mmHg. QOL was significantly improved by TCPM plus antihypertensive drugs compared with antihypertensive drugs alone. This systematic review provided the first classification of clinical evidence for the effectiveness of TCPM for EH. The usage of TCPMs for EH was supported by evidence of class level III. As a result of the methodological drawbacks of the included studies, more rigorously designed randomized controlled trials that focus on mortality and cardiovascular events during long-term follow-up are warranted before TCPM can be recommended for hypertensive patients. Two TCPMs, Song ling xue mai kang capsules and Yang xue qing nao granules, should be prioritized for further research.
authors: From the Department of Cardiology, Guang'anmen Hospital (XX); Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China (PW); Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada (YZ); and Bio-organic and Natural Products Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts, USA (XL).
authors: Xingjiang
authors: X
authors: Xiong
authors: Pengqian
authors: P
authors: Wang
authors: Yuqing
authors: Y
authors: Zhang
authors: Xiaoke
authors: X
authors: Li
mesh_terms: D001794:Blood Pressure / Q000187:drug effects; D002681:China; D018450:Disease Progression; D000075222:Essential Hypertension; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008516:Medicine, Chinese Traditional / Q000009:adverse effects / Q000379:methods*; D011788:Quality of Life
references: Evid Based Complement Alternat Med. 2012;2012:268542
references: 22550539
references: Circulation. 2007 Jun 19;115(24):3121-9
references: 17548730
references: N Engl J Med. 1986 Jun 26;314(26):1657-64
references: 3520318
references: Evid Based Complement Alternat Med. 2013;2013:275279
references: 23878594
references: Hypertens Res. 2013 Jul;36(7):570-9
references: 23552514
references: Lancet. 2002 Nov 2;360(9343):1347-60
references: 12423980
references: Hypertension. 2006 Nov;48(5):838-45
references: 17015784
references: Lancet. 2003 May 10;361(9369):1629-41
references: 12747893
references: Trends Pharmacol Sci. 2013 Nov;34(11):620-8
references: 24139610
references: Lancet. 2008 May 3;371(9623):1513-8
references: 18456100
references: J Am Coll Cardiol. 2005 Jul 5;46(1):184-221
references: 15992662
references: Evid Based Complement Alternat Med. 2014;2014:809741
references: 25525450
references: JAMA. 2014 Feb 5;311(5):507-20
references: 24352797
references: Evid Based Complement Alternat Med. 2013;2013:978398
references: 23861720
references: Arch Intern Med. 2002 Jan 28;162(2):133-40
references: 11802746
references: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Sep;21(9):660-2
references: 12575551
references: Ann Intern Med. 2006 Mar 7;144(5):364-7
references: 16520478
references: Annu Rev Pharmacol Toxicol. 2003;43:463-84
references: 12540748
references: Evid Based Complement Alternat Med. 2012;2012:284847
references: 22194771
references: Lancet. 2002 Dec 14;360(9349):1903-13
references: 12493255
references: Evid Based Complement Alternat Med. 2012;2012:697237
references: 23346210
references: Zhong Xi Yi Jie He Xue Bao. 2009 Jun;7(6):509-13
references: 19583930
references: J Am Coll Cardiol. 2010 Feb 9;55(6):515-25
references: 20152556
references: Phytomedicine. 2014 Sep 15;21(10):1131-6
references: 24877716
references: Hypertension. 2013 Jun;61(6):1360-83
references: 23608661
references: J Am Coll Cardiol. 2012 Aug 14;60(7):599-606
references: 22796254
references: Am J Hypertens. 2009 Jan;22(1):122-8
references: 19008863
references: Ann Intern Med. 2010 Jun 1;152(11):726-32
references: 20335313